Updated ROCK-1 data at #EHA2026 show that rocbrutinib continues to deliver activity in R/R #MCL previously treated w/ a covalent BTK inhibitor. #lymsm
✅ ORR of 63.9%, including a 23.0% CR rate
✅ Median DOR of 16.46 months
✅ Median OS NR at 23.36 months of follow-up
onclive.com/view/rocbrut...
Rocbrutinib delivered durable responses and encouraging survival with manageable safety in BTK inhibitor–pretreated relapsed/refractory MCL.
